RELMADA THERAPEUTICS, INC. (RLMD) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$3.11

From 52W high−59.80%

Volume746297.00

Market cap$337.08M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataOct 19, 2026

Open

$3.11

From 52W high

−59.80%

Volume

746297.00

Market cap

$337.08M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−1.9x

P/E (TTM)

—

RSI (14)

31.2

MomentumView details →

1D Return

+1.94%

YTD Return

−34.78%

SummaryUpdated Jun 1, 2026

Relmada Therapeutics, Inc. (NASDAQ:RLMD) is a clinical-stage biotechnology company founded in 2004 and headquartered in Coral Gables, Florida. The company has evolved from focusing primarily on a single drug candidate for depression treatment to building a diversified pipeline of central nervous system therapies and other medical treatments. After going public in 2014, Relmada has undergone significant strategic pivots in recent years, including acquiring new product candidates and expanding beyond its original depression treatment focus following mixed clinical trial results.

Ask drillr about RELMADA THERAPEUTICS, INC. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−1.9x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

1.6x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−29.98%

ROA (TTM)

−28.27%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+58.56%

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

+45.28%

EBITDA YoY

—

MomentumView details →

1D Return

+1.94%

YTD Return

−34.78%

1Y Return

+39.38%

RSI (14)

31.2

vs 50D SMA

−23.01%

vs 200D SMA

−41.62%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

29.52x

Quick Ratio

29.52x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.11

EPS Surprise

44.87%

Beats (12Q)

6/12

Next Q EPS Est

−$0.16

Avg Surprise (4Q)

−180.05%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−61.93M

Op. CF (TTM)

−45.99M

Next earningsNov 12, 2026 →

Latest newsMore news →

Relmada Therapeutics announced it is prioritizing manufacturing activities for NDV-01, its sustained-release intravesical formulation of gemcitabine and docetaxel for non-muscle invasive bladder cancer, targeting an investigational new drug application filing by the end of 2026.74d ago

Similar companies

Nautilus Biotechnology, Inc.NAUT Orchestra BioMed Holdings, Inc.OBIO Enanta Pharmaceuticals, Inc.ENTA Turn Therapeutics Inc.TTRX Atea Pharmaceuticals, Inc.AVIR Galectin Therapeutics Inc.GALT Find similar companies →

Latest newsMore news →